Inventiva (NASDAQ:IVA) Shares Down 3.8%

Inventiva S.A. (NASDAQ:IVAGet Rating) shares dropped 3.8% during trading on Tuesday . The company traded as low as $6.16 and last traded at $6.28. Approximately 8,065 shares traded hands during mid-day trading, an increase of 6% from the average daily volume of 7,644 shares. The stock had previously closed at $6.53.

Analyst Ratings Changes

Separately, Societe Generale cut Inventiva from a “buy” rating to a “sell” rating in a report on Tuesday, November 15th.

Inventiva Stock Performance

The business has a fifty day moving average of $4.69 and a 200 day moving average of $4.70. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.16 and a quick ratio of 4.14.

Institutional Trading of Inventiva

A hedge fund recently raised its stake in Inventiva stock. Yiheng Capital Management L.P. raised its position in Inventiva S.A. (NASDAQ:IVAGet Rating) by 59.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,640,253 shares of the company’s stock after purchasing an additional 982,679 shares during the quarter. Inventiva accounts for approximately 0.9% of Yiheng Capital Management L.P.’s portfolio, making the stock its 21st largest position. Yiheng Capital Management L.P. owned about 6.46% of Inventiva worth $14,970,000 at the end of the most recent reporting period. 21.86% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

(Get Rating)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

Read More

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.